NCT05797259View on ClinicalTrials.gov

RANKL Antibody for Acute Charcot Neuro-osteoarthropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 10, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Charcot Joint of Foot
Interventions
DRUG

Danosumab

60 mg subcutaneous Danosumab

OTHER

Normal Saline

Placebo comparator arm

Trial Locations (1)

160012

Deptt of Endocrinology, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT05797259 - RANKL Antibody for Acute Charcot Neuro-osteoarthropathy | Biotech Hunter | Biotech Hunter